TY - JOUR
T1 - Basal values and changes of liver stiffness predict the risk of disease progression in compensated advanced chronic liver disease
AU - Pons, Mònica
AU - Simón-Talero, Macarena
AU - Millán, Laura
AU - Ventura-Cots, Meritxell
AU - Santos, Begoña
AU - Augustin, Salvador
AU - Genescà, Joan
PY - 2016/10/1
Y1 - 2016/10/1
N2 - © 2016 Editrice Gastroenterologica Italiana S.r.l. Background and aims Transient elastography has been proposed as a tool to predict the risk of decompensation in patients with chronic liver disease. We aimed to identify risk groups of disease progression, using a combination of baseline liver stiffness measurement (LSM) and its change over time (delta-LSM) in patients with compensated advanced chronic liver disease (cACLD). Methods Ninety-four patients with baseline LSM ≥10 kPa, Child–Pugh score 5 and without previous decompensation were included. A second LSM was performed during follow-up and data on liver function and liver-related events were collected. The primary endpoint was a composite that included death, liver decompensation and impairment in at least 1 point in Child–Pugh score. Results After a median follow-up of 43.6 months, 15% of patients presented the primary endpoint. Multivariate analysis identified baseline LSM (OR 1.12, P = 0.002) and delta-LSM (OR 1.02, P = 0.048) as independent predictors of the primary endpoint. A high risk group represented by patients with baseline LSM ≥21 kPa and delta-LSM ≥10% (risk of progression 47.1%, 95% CI: 23–71%) was identified, while patients with LSM <21 kPa and delta-LSM <10% presented zero risk of progression (P = 0.03). Conclusions Simple classification rules using baseline LSM and delta-LSM identify cACLD patients at low or high risk of disease progression.
AB - © 2016 Editrice Gastroenterologica Italiana S.r.l. Background and aims Transient elastography has been proposed as a tool to predict the risk of decompensation in patients with chronic liver disease. We aimed to identify risk groups of disease progression, using a combination of baseline liver stiffness measurement (LSM) and its change over time (delta-LSM) in patients with compensated advanced chronic liver disease (cACLD). Methods Ninety-four patients with baseline LSM ≥10 kPa, Child–Pugh score 5 and without previous decompensation were included. A second LSM was performed during follow-up and data on liver function and liver-related events were collected. The primary endpoint was a composite that included death, liver decompensation and impairment in at least 1 point in Child–Pugh score. Results After a median follow-up of 43.6 months, 15% of patients presented the primary endpoint. Multivariate analysis identified baseline LSM (OR 1.12, P = 0.002) and delta-LSM (OR 1.02, P = 0.048) as independent predictors of the primary endpoint. A high risk group represented by patients with baseline LSM ≥21 kPa and delta-LSM ≥10% (risk of progression 47.1%, 95% CI: 23–71%) was identified, while patients with LSM <21 kPa and delta-LSM <10% presented zero risk of progression (P = 0.03). Conclusions Simple classification rules using baseline LSM and delta-LSM identify cACLD patients at low or high risk of disease progression.
KW - Compensated advanced chronic liver disease (cACLD)
KW - Liver stiffness
KW - Prognosis
U2 - 10.1016/j.dld.2016.06.019
DO - 10.1016/j.dld.2016.06.019
M3 - Article
SN - 1590-8658
VL - 48
SP - 1214
EP - 1219
JO - Digestive and Liver Disease
JF - Digestive and Liver Disease
IS - 10
ER -